Imkeldi (imatinib) – New drug approval

Site Logo

Search

Contact our sales team

Provide your contact details below, so one of our product specialists can schedule a call.

Need help or account access? View our support resources or sign in.

* = Required Field
First name
Last name
Email address
Country
Phone
Job Title:
Job function
Job level:
Company
Company type
Solution of interest
Comments/How can we help?

By submitting the form, you are agreeing to the Optum Terms of Use and Privacy Policy.

SF/GO Parent Program Name_hidden
Product Taxonomy Product Segment_hidden
Product Taxonomy Product Sub Segment_hidden
Product Taxonomy Product Unit_hidden
Product Taxonomy Product Family_hidden
Product PIM Product ID_hidden
ID SF/GO: Campaign ID_hidden
ID SF/GO: Campaign Name_hidden
Person Notes Text Area_hidden
UUID_hidden

Get in touch

Contact our sales team
Connect with us for solutions or services.

Customer sign-in
Access our customer portals.
Optum Provider Portal   Optum Pay All Sign-in Portals

Support and resources
Manage your account, find resources and more.
Payer lists   Enrollment forms   Product Support portals   Claims
Rx Prior Authorization   Join Our Team   All Support

Imkeldi (imatinib) – New drug approval

November 22, 2024 - The FDA approved Shorla Oncology’s Imkeldi (imatinib) oral solution.

back to top